A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC

Trial Profile

A P1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Tocagen
  • Most Recent Events

    • 07 Aug 2018 According to a Tocagen media release, data from this study will be presented at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.
    • 21 May 2018 Status changed from active, no longer recruiting to completed.
    • 10 May 2018 Results were presented the 2018 American Academy of Neurology (AAN) Annual Meeting and 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top